Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Helmut Friess

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6029-5857; OpenAlex author ID A5006574809, A5008274335, A5018466754, A5054623518, A5110132975, A5160445702. Sources: ClinicalTrials.gov.

Their work

Papers
65 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
222
Papers, trials and grants by year

2011: 7 papers, 1 trial · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 5 papers · 2018: 3 papers · 2019: 4 papers · 2020: 4 papers · 2021: 7 papers · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 9 papers · 2026: 6 papers

Papers 50 of 65

  1. Prognostic implications of superior mesenteric vein/portal vein resection and histologic venous invasion in BR/LA PDAC after neoadjuvant therapy. Co-author DOI 10.1007/s00423-026-04145-9↗
  2. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Co-author DOI 10.1007/s13304-026-02651-5↗
  3. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  4. Paclitaxel and triptolide impair MYC-driven cell cycle via suppressing chromatin reprogramming in ALDH1A3High pancreatic cancer. Co-author DOI 10.1016/j.phymed.2026.158351↗
  5. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  6. Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers18071131↗
  7. Clinical characteristics of pancreatic cancer presenting with acute pancreatitis: a propensity-matched cohort study. Co-author DOI 10.1007/s00464-025-11654-z↗
  8. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2025.217894↗
  9. Pancreatic cancer cells infiltrate nerves through TGFbeta1-driven perineural epithelial-to-mesenchymal-like transdifferentiation. Co-author DOI 10.1016/j.neo.2025.101126↗
  10. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  11. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  12. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  13. Neural crossroads of pancreatic cancer: how nociceptors drive tumor progression and immune evasion. First author DOI 10.1038/s41422-025-01124-5↗
  14. Editor's Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4286↗
  15. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  16. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Co-author DOI 10.1002/2056-4538.12377↗
  17. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  18. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Co-author DOI 10.1038/s41598-024-77010-8↗
  19. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  20. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  21. Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000302↗
  22. The Effect of Celiac Neurolysis and Splanchnicectomy on Survival in Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1159/000520456↗
  23. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? Co-author DOI 10.1159/000521847↗
  24. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  25. Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Co-author DOI 10.3390/cancers14194582↗
  26. Innervated mouse pancreas organoids as an ex vivo model to study pancreatic neuropathy in pancreatic cancer. Co-author DOI 10.1016/j.xpro.2021.100935↗
  27. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  28. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  29. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  30. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
  31. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-332↗
  32. Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Co-author DOI 10.3390/cancers13092069↗
  33. [Nutritional therapies for patients with pancreatic cancer]. First author DOI 10.1007/s15006-020-4495-4↗
  34. Future directions of neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.18632/oncoscience.506↗
  35. Pancreatic cancer. Co-author DOI 10.21037/tgh.2019.12.15↗
  36. Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9030724↗
  37. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Co-author DOI 10.1186/s41747-019-0119-0↗
  38. Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological … Co-author DOI 10.1371/journal.pone.0208717↗
  39. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer. Last author DOI 10.21037/tgh.2019.04.09↗
  40. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  41. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2018.07.003↗
  42. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  43. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and… Co-author DOI 10.1186/s12885-018-4055-9↗
  44. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  45. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.suronc.2017.01.007↗
  46. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Co-author DOI 10.1073/pnas.1606909114↗
  47. Epigenomic therapies: the potential of targeting SIRT6 for the treatment of pancreatic cancer. Last author DOI 10.1080/14728222.2017.1265507↗
  48. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2432↗
  49. Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. Co-author DOI 10.1136/gutjnl-2015-309784↗
  50. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? Co-author DOI 10.4103/0971-5851.195731↗

Trials 1

  1. Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer Principal investigator NCT01419002↗

Closest collaborators

The 25 strongest of 222 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 27 shared papers, 2011–2026 · strength 4.83
  2. Guralp Onur Ceyhan · 20 shared papers, 2011–2026 · strength 2.71
  3. Carmen Mota Reyes · 11 shared papers, 2017–2026 · strength 1.96
  4. Florian Scheufele · 6 shared papers, 2017–2026 · strength 1.37
  5. Ilaria Pergolini · 7 shared papers, 2022–2026 · strength 1.36
  6. Stephan Schorn · 8 shared papers, 2016–2025 · strength 1.19
  7. Rüdiger Göß · 7 shared papers, 2017–2025 · strength 1.17
  8. Jorg H. Kleeff · 15 shared papers, 2011–2025 · strength 1.06
  9. Okan Safak · 6 shared papers, 2022–2025 · strength 1.03
  10. Alexander Muckenhuber · 7 shared papers, 2017–2025 · strength 0.95
  11. Marc Eric Martignoni · 5 shared papers, 2018–2026 · strength 0.89
  12. Rickmer Braren · 8 shared papers, 2017–2025 · strength 0.89
  13. Hana Algül · 9 shared papers, 2016–2026 · strength 0.85
  14. Alexander Novotny · 5 shared papers, 2011–2026 · strength 0.84
  15. Christoph W. Michalski · 12 shared papers, 2011–2026 · strength 0.83
  16. Hongzhen Li · 5 shared papers, 2021–2026 · strength 0.81
  17. Shuang Nie · 5 shared papers, 2018–2026 · strength 0.78
  18. Wilko Weichert · 8 shared papers, 2017–2022 · strength 0.72
  19. Mert Erkan · 8 shared papers, 2011–2026 · strength 0.70
  20. Dieter Saur · 4 shared papers, 2022–2026 · strength 0.69
  21. Bo Kong · 10 shared papers, 2011–2022 · strength 0.64
  22. Georgios A. Kaissis · 5 shared papers, 2019–2025 · strength 0.62
  23. Roland Michael Schmid · 6 shared papers, 2017–2025 · strength 0.62
  24. Xiaoping Zou · 5 shared papers, 2018–2025 · strength 0.61
  25. Anna Melissa Schlitter · 5 shared papers, 2017–2025 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.